Company news

Cynata Therapeutics Limited news in 2025

Cynata Therapeutics Limited's news releases, calls and decks from 2025, newest first.

View company

Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial

December 14, 2025

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

December 14, 2025

Positive DSMB Review in Phase 1/2 Kidney Transplant Trial

December 3, 2025

Final Patient Visit Complete in Phase 3 Osteoarthritis Trial

November 23, 2025

Cynata Receives $1.7m R&D Tax Incentive Refund

November 5, 2025

September 2025 Quarterly Activity Report and Appendix 4C

October 31, 2025

Appendix 4E & Annual Report

August 28, 2025

At-the-Market Subscription Agreement

August 21, 2025

June 2025 Quarterly Activity Report and Appendix 4C

July 30, 2025

CYP-001s FDA Approval Pathway Not Impeded

May 16, 2025

March 2025 Quarterly Activity Report and Appendix 4C

April 24, 2025

Publication comparing Cymerus MSCs to other MSCs

February 4, 2025

Quarterly Activity Report & Appendix 4C

January 29, 2025

Decks in 2025